Over 90% of United States and Canadian children and adolescents with cancer are enrolled in Children's Oncology Group (COG) clinical trials with no racial, ethnic or geographic bias to registration, allowing for near- population-based clinical, translational and basic research. Clinical trials conducted by COG and its antecedent organizations have played a major role in these advances and will continue to drive the improvements projected to come in the next decade. The biospecimens collected during these clinical treatment trials are crucial to their success. These biospecimens are sent to centralized laboratories for clinical testing and banking for future research use. The Biopathology Center (BPC) is part of the Research Institute at Nationwide Children's Hospital in Columbus, Ohio and houses the COG Solid Tissue Bank as well as the COG ALL Molecular Reference Laboratory and Bank. The COG AML Reference Laboratory and Bank is located at the Fred Hutchinson Cancer Research Center Seattle, Washington. Currently, the BPC is federally funded to serve several clients (including the Pediatric Division of the Cooperative Human Tissue Network [pCHTN], and the biobanking efforts of the Gynecologic Oncology Group [GOG], the Childhood Cancer Survivor Study [CCSS], and the Cancer Therapy Evaluation Program [CTEP]). To accomplish this, the banks continue to work with the aims of the original grant submission in 2004. 1. Establish collection, storage and quality control procedures for tissue banking in pediatric cancer patients that are near-population-based. 2. Ensure proper storage and quality control procedures for pediatric tissue bank biospecimens that promote outstanding retrospective translational research. 3. Ensure proper administration of tissue bank resources to facilitate investigator access to biospecimens. 4. Promote linkage of tissue bank resources to existing demographic, clinical, and biological, treatment and outcome data. 5. Optimize utilization of finite tissue bank resources utilizing emerging technologies.

Public Health Relevance

Today, over 80% of children with cancer are expected to be cured, with an approximately 50% decrease in mortality rate between 1975 and 2006. Five-year survival rates for acute myeloid leukemia (AML) and neuroblastoma have seen vast improvements. AML survival increased from under 50% to 60% and neuroblastoma survival rose from 65% to 75%. The higher survival rates of patients with acute lymphoblastic leukemia (ALL) improved from 86.8% to 89.0%. COG research has played a major role in improvements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
7U24CA114766-07
Application #
8337743
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (M1))
Program Officer
Lubensky, Irina
Project Start
2005-08-03
Project End
2014-03-31
Budget Start
2012-06-21
Budget End
2013-03-31
Support Year
7
Fiscal Year
2012
Total Cost
$1,329,162
Indirect Cost
$487,507
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Liu, Chengcheng; Yang, Wenjian; Devidas, Meenakshi et al. (2016) Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol 34:2133-40
Cajaiba, Mariana M; Jennings, Lawrence J; Rohan, Stephen M et al. (2016) Expanding the Spectrum of Renal Tumors in Children: Primary Renal Myoepithelial Carcinomas With a Novel EWSR1-KLF15 Fusion. Am J Surg Pathol 40:386-94
Ooms, Ariadne H A G; Gadd, Samantha; Gerhard, Daniela S et al. (2016) Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res :
Temple, William; Mendelsohn, Lori; Kim, Grace E et al. (2016) Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging 43:474-81
O'Suoji, Chibuzo; Welch, Jennifer J G; Perkins, Sherrie L et al. (2016) Rare Pediatric Non-Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1. Pediatr Blood Cancer 63:794-800
Matlawska-Wasowska, K; Kang, H; Devidas, M et al. (2016) MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study. Leukemia 30:1909-12
Liu, C; Yang, W; Pei, D et al. (2016) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther :
Xu, Lin; Wilson, Raphael A; Laetsch, Theodore W et al. (2016) Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group. Sci Rep 6:33429
Hungate, Eric A; Vora, Sapana R; Gamazon, Eric R et al. (2016) A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun 7:10635
Matloub, Yousif; Stork, Linda; Asselin, Barbara et al. (2016) Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia-Comparison among Different Treatment Strategies. Pediatr Blood Cancer 63:255-61

Showing the most recent 10 out of 133 publications